HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Ashrafi, G. H. Articles by Campo, M. S. Search for Related Content PubMed PubMed Citation Articles by Ashrafi, G. H. Articles by Campo, M. S. Agricola Articles by Ashrafi, G. H. Articles by Campo, M. S.

Vaccination of sarcoid-bearing donkeys with chimeric virus-like particles of bovine papillomavirus type 1

G. H. Ashrafi^1,

¹ Division of Pathological Sciences, Institute of Comparative Medicine, University of Glasgow, Glasgow G61 1QH, UK
² Deutsches Krebsforschungszentrum, Forschungsschwerpunkt Angewandte Tumorvirologie, Im Neuenheimer Feld 242, Heidelberg, Germany
³ The Donkey Sanctuary, Veterinary Department, Salcombe Regis, Sidmouth, UK
⁴ Comparative Epidemiology and Informatics, Institute of Comparative Medicine, University of Glasgow, Glasgow G61 1QH, UK

Correspondence
M. S. Campo
s.campo{at}vet.gla.ac.uk

Equine sarcoids are fibroblastic skin tumours affecting equids worldwide. While the pathogenesis is not entirely understood, infection with bovine papillomavirus (BPV) type 1 (and less commonly type 2) has been implicated as a major factor in the disease process. Sarcoids very seldom regress and in fact often recrudesce following therapy. Nothing is known about the immune response of the equine host to BPV. Given that the viral genes are expressed in sarcoids, it is reasonable to assume that vaccination of animals against the expressed viral proteins would lead to the induction of an immune response against the antigens and possible tumour rejection. To this end we vaccinated sarcoid-bearing donkeys in a placebo-controlled trial using chimeric virus-like particles (CVLPs) comprising BPV-1 L1 and E7 proteins. The results show a tendency towards enhanced tumour regression and reduced progression in the vaccinated group compared to control animals. Although promising, further studies are required with larger animal groups to definitely conclude that vaccination with CVLPs is a potential therapy for the induction of sarcoid regression.

Present address: Division of Pharmaceutical Sciences, Strathclyde Institute of Pharmacy & Biomedical Sciences (SIPBS), John Arbuthnott Building, University of Strathclyde, Glasgow, UK.